Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Ionis Pharmaceuticals stock
Learn how to easily invest in Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals Inc is a biotechnology business based in the US. Ionis Pharmaceuticals shares (IONS) are listed on the NASDAQ and all prices are listed in US Dollars. Ionis Pharmaceuticals employs 660 staff and has a trailing 12-month revenue of around $848.8 million.
How to buy shares in Ionis Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IONS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- IONS shares summary
- Compare share dealing platforms
- Is IONS stock a buy or sell?
- Stock performance over time
- Is IONS suitable for ethical investing?
- Are IONS shares over-valued?
- Ionis Pharmaceuticals's financials
- How volatile are IONS shares?
- Does Ionis Pharmaceuticals pay a dividend?
- Other common questions
Ionis Pharmaceuticals stock price (NASDAQ: IONS)Use our graph to track the performance of IONS stocks over time.
Ionis Pharmaceuticals shares at a glance
|Latest market close||$43.23|
|52-week range||$25.04 - $48.82|
|50-day moving average||$42.07|
|200-day moving average||$36.43|
|Wall St. target price||$50.17|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.03|
Buy Ionis Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Ionis Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Ionis Pharmaceuticals price performance over time
|1 week (2022-09-15)||-8.97%|
|1 month (2022-08-22)||-1.79%|
|3 months (2022-06-23)||10.79%|
|6 months (2022-03-22)||19.16%|
|1 year (2021-09-24)||19.42%|
|2 years (2020-09-25)||-11.23%|
|3 years (2019-09-26)||59.32|
|5 years (2017-09-26)||52.4|
Is Ionis Pharmaceuticals stock undervalued or overvalued?
Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ionis Pharmaceuticals's PEG ratio
Ionis Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 25.7033. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ionis Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ionis Pharmaceuticals's EBITDA
Ionis Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14 million.
The EBITDA is a measure of a Ionis Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Ionis Pharmaceuticals financials
|Revenue TTM||$848.8 million|
|Gross profit TTM||$164.6 million|
|Return on assets TTM||-0.09%|
|Return on equity TTM||-4.66%|
|Market capitalisation||$6.6 billion|
TTM: trailing 12 months
Ionis Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ionis Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Ionis Pharmaceuticals's total ESG risk score
Total ESG risk: 36.64
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ionis Pharmaceuticals's overall score of 36.64 (as at 12/31/2018) is pretty weak – landing it in it in the 62nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Ionis Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Ionis Pharmaceuticals's environmental score
Environmental score: 5.18/100
Ionis Pharmaceuticals's environmental score of 5.18 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Ionis Pharmaceuticals's social score
Social score: 26.17/100
Ionis Pharmaceuticals's social score of 26.17 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Ionis Pharmaceuticals's governance score
Governance score: 13.29/100
Ionis Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Environmental, social, and governance (ESG) summary
|Total ESG score||36.64|
|Total ESG percentile||62.18|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
Ionis Pharmaceuticals share dividends
We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months.
Ionis Pharmaceuticals share price volatility
Over the last 12 months, Ionis Pharmaceuticals's shares have ranged in value from as little as $25.04 up to $48.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 0.6388. This would suggest that Ionis Pharmaceuticals's shares are less volatile than average (for this exchange).
Ionis Pharmaceuticals overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc. ; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc.
Ionis Pharmaceuticals in the news
Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
Frequently asked questionsWhat percentage of Ionis Pharmaceuticals is owned by insiders or institutions?
Currently 0.591% of Ionis Pharmaceuticals shares are held by insiders and 87.954% by institutions. How many people work for Ionis Pharmaceuticals?
Latest data suggests 660 work at Ionis Pharmaceuticals. When does the fiscal year end for Ionis Pharmaceuticals?
Ionis Pharmaceuticals's fiscal year ends in December. Where is Ionis Pharmaceuticals based?
Ionis Pharmaceuticals's address is: 2855 Gazelle Court, Carlsbad, CA, United States, 92010 What is Ionis Pharmaceuticals's ISIN number?
Ionis Pharmaceuticals's international securities identification number is: US4622221004 What is Ionis Pharmaceuticals's CUSIP number?
Ionis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 462222100
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert